ClinicalTrials.gg
CompletedNCT07237867Motor_pPNSUpdated Nov 16, 2026

Frequency-Dependent Effects of Percutaneous Femoral Nerve Stimulation on Quadriceps Strength

An interventional study of High-frequency percutaneous femoral nerve stimulation and Low-frequency percutaneous femoral nerve stimulation in Patellar Tendinopathy, sponsored by Hospital Clinic of Barcelona. Completed at 1 site in Spain. Open to male participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now CompletedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Musculoskeletal Pain with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Musculoskeletal Pain · Spain.

Enrollment
29th of 30
19 · median 66
Started
2025
with 2 others
No phase
27 of 45
8 open now
Registered
37th of 45
by date

Among the 45 studies in Musculoskeletal Pain with a site in Spain, this one is the 29th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2025, is one of 27 with no phase, and was the 37th registered.

Musculoskeletal Pain

518 studies on the registry are indexed under Musculoskeletal Pain; 127 are open to participants now.

Browse Musculoskeletal Pain studies →

Open to participants now

11 of the 45 studies in Musculoskeletal Pain with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 66 Musculoskeletal Pain studies recruiting now, 30 (45%) set no upper age limit and 30 (45%) stop at 75 or younger; 8 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 40 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Musculoskeletal Pain with a site in Spain, or all of them as a file.
02

Study summary

Peripheral nerve stimulation (PNS) is used to manage musculoskeletal pain and may also influence the neural mechanisms involved in voluntary muscle activation. However, whether different stimulation protocols produce distinct effects on muscle strength in individuals with persistent musculoskeletal pain remains unclear.

This randomized, blinded, crossover clinical trial investigates the acute effects of three femoral nerve stimulation protocols on quadriceps muscle function in individuals with persistent patellar tendinopathy. Each participant receives three interventions in a randomized sequence, separated by washout periods of at least 7 days: (1) high-frequency percutaneous peripheral nerve stimulation (HF-pPNS; 100 Hz), (2) low-frequency percutaneous peripheral nerve stimulation (LF-pPNS; 2 Hz), and (3) sensory-level transcutaneous electrical nerve stimulation (s-TENS; 100 Hz). Percutaneous interventions are administered under ultrasound guidance, whereas s-TENS is delivered using surface electrodes.

Quadriceps maximal voluntary contraction (MVC) and rate of force development (RFD) are assessed before stimulation and at 2, 10, 15, and 30 minutes after each intervention. Pain experienced during muscle strength testing, intervention tolerability, and adverse events are also evaluated.

The primary objective is to determine whether these stimulation protocols produce different acute changes in voluntary quadriceps force production. The study also examines interindividual variability in motor responses and explores their associations with pain during voluntary contraction and baseline clinical status.

03

Conditions studied

  • Patellar Tendinopathy

Browse trials for

Keywords

  • Peripheral nerve stimulation
  • Percutaneous neuromodulation
  • Transcutaneous electrical nerve stimulation
  • Musculoskeletal pain
  • Patellar tendinopathy
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-40 years.
  • Individuals with clinically diagnosed patellar tendinopathy lasting ≥3 months.
  • Ultrasound findings consistent with patellar tendinopathy, including tendon thickening, hypoechoic areas, or neovascularization.
  • Pain during tendon-loading activities (e.g., jumping, running, or squatting).
  • Ability to perform maximal voluntary isometric quadriceps contractions and comply with all experimental procedures and sessions.
  • Ability and willingness to provide written prior to participation.

Exclusion criteria

Exclusion Criteria

  • Knee surgery or traumatic knee injury within the preceding 12 months.
  • Partial or complete patellar tendon rupture.
  • Neurological or neuromuscular disorders affecting lower-limb motor function, including radiculopathy or peripheral neuropathy.
  • to electrical stimulation or percutaneous procedures, including implanted electrical devices, skin infections, or open wounds at the stimulation site.
  • Use of analgesics or anti-inflammatory medications, or receipt of injections, within the preceding 48 hours.
  • Participation in another interventional study within the preceding 30 days.
  • Pregnancy or suspected pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    High-frequency percutaneous peripheral nerve stimulation (HF-pPNS)

    Participants receive HF-pPNS as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

    Device: High-frequency percutaneous femoral nerve stimulation

  • Experimental
    Low-frequency percutaneous peripheral nerve stimulation (LF-pPNS)

    Participants receive LF-pPNS as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

    Device: Low-frequency percutaneous femoral nerve stimulation

  • Active comparator
    Sensory-level transcutaneous femoral nerve stimulation (s-TENS)

    Participants receive s-TENS targeting the femoral nerve as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

    Device: Transcutaneous electrical nerve stimulation

Interventions

  • DeviceHigh-frequency percutaneous femoral nerve stimulation

    High-frequency percutaneous peripheral nerve stimulation (HF-pPNS) is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Valencia, Spain), which generates symmetrical biphasic pulses. The femoral nerve is identified at the inguinal level using a SonoScape E1 Exp ultrasound system (SonoScape Medical Corp., Shenzhen, China). Under real-time ultrasound guidance, a sterile acupuncture needle (0.30 × 50 mm) is inserted in-plane and positioned lateral to the femoral nerve, avoiding adjacent vessels. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Stimulation is administered at 100 Hz in five 5-second trains separated by 55-second rest intervals. Intensity is adjusted to the highest pain-free current eliciting visible quadriceps contraction. Participants receive one session, with at least 7 days between crossover conditions.

    Also known as: HF-pPNS

  • DeviceLow-frequency percutaneous femoral nerve stimulation

    Low-frequency percutaneous peripheral nerve stimulation (LF-pPNS) is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Valencia, Spain), which generates symmetrical biphasic pulses. The femoral nerve is identified at the inguinal level using a SonoScape E1 Exp ultrasound system (SonoScape Medical Corp., Shenzhen, China). Under real-time ultrasound guidance, a sterile acupuncture needle (0.30 × 50 mm) is inserted in-plane and positioned lateral to the femoral nerve, avoiding adjacent vessels. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Stimulation is administered continuously at 2 Hz for 16 minutes. Intensity is adjusted to the highest pain-free current eliciting visible quadriceps contraction. Participants receive one session, with at least 7 days between crossover conditions.

    Also known as: LF-pPNS

  • DeviceTranscutaneous electrical nerve stimulation

    Sensory-level transcutaneous electrical nerve stimulation (s-TENS) is administered targeting the femoral nerve at the inguinal level. The femoral nerve is identified under ultrasound guidance (SonoScape E1 Exp, SonoScape Medical Corp., China), and a self-adhesive surface electrode (5 × 5 cm) is positioned over the nerve. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Electrical stimulation is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Spain), generating symmetrical biphasic pulses continuously at 100 Hz for 16 minutes. Intensity is individually adjusted to elicit a clear paresthetic sensation without visible quadriceps contraction. Each participant receives one s-TENS session, with a minimum 7-day washout between crossover conditions.

    Also known as: s-TENS

06

What researchers measure

Primary outcomes

  1. Change in Quadriceps Maximal Isometric Voluntary Contraction

    Quadriceps maximal voluntary isometric contraction (MVC) is measured on the symptomatic limb using a Chronojump Force Sensor Kit (Chronojump, Barcelona, Spain). Participants are seated with the hip flexed at 90° and the knee positioned at 60°. Following a standardized warm-up and familiarization procedure, participants perform three 4-second maximal voluntary isometric knee-extension contractions, separated by 10-second rest intervals. Real-time visual force feedback is provided, and participants are instructed to contract as fast and as hard as possible from a relaxed state. MVC is defined as the highest peak force recorded across the three trials, expressed in Newtons (N). Absolute and relative changes from baseline are assessed following each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS).

    Time frame: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.

Secondary outcomes

  1. Change in Quadriceps Rate of Force Development

    Quadriceps rate of force development (RFD) is assessed on the symptomatic limb using a Chronojump Force Sensor Kit (Chronojump, Barcelona, Spain). Participants perform three 4-second maximal voluntary isometric knee-extension contractions, separated by 10-second rest intervals, while instructed to contract as fast and as hard as possible. RFD is calculated from the force-time curve as the slope of force increase during the first 250 milliseconds following contraction onset, expressed in Newtons per second (N/s). Absolute and relative changes from baseline are assessed following each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS).

    Time frame: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.

  2. Incidence of Adverse Events Assessed Through Post-Intervention Questionnaires

    Adverse events potentially associated with peripheral nerve stimulation are assessed using a structured questionnaire completed at the end of each experimental session. Participants report the presence and intensity of sensory symptoms (pain, burning, itching), local skin reactions (erythema, swelling, bruising), and systemic symptoms (fatigue, headache, nausea). Additional unexpected symptoms can also be reported. Symptom intensity is assessed using a numerical rating scale (NRS; 0-10). Adverse events are recorded by type and severity, and their incidence is expressed as the number and percentage of participants reporting each event under each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS). Differences in adverse event frequency and intensity are evaluated across stimulation conditions.

    Time frame: Immediately after each intervention session.

  3. Pain Intensity Evoked by Quadriceps Contraction

    Pain intensity experienced during quadriceps maximal voluntary isometric contraction (MVC) is assessed using a 10-cm visual analog scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Participants report the intensity of pain experienced during the strength-testing procedure immediately after its completion. Pain scores are recorded for each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS) to characterize pain experienced during voluntary force production and explore its association with changes in quadriceps strength.

    Time frame: Immediately after post-intervention quadriceps strength testing during each experimental session.

07

Study locations

1 site
  • Blanquerna University
    Barcelona, Barcelona 08020, Spain
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the published article will be available from the corresponding author upon reasonable request. These data may include maximal voluntary contraction (MVC), rate of force development (RFD), pain ratings, baseline clinical characteristics, stimulation conditions, and adverse events. Data sharing will be subject to applicable ethical approvals, institutional policies, and data protection requirements. Requests will be evaluated based on their scientific rationale and methodological soundness.

Time frame: De-identified individual participant data will be available upon reasonable request beginning at the time of publication of the study results and for a period of five years thereafter.

Access criteria: De-identified individual participant data underlying the published results will be available to qualified researchers upon reasonable request to the corresponding author. Requests must include a scientifically sound research proposal describing the intended use of the data. Access will be subject to approval by the research team and compliance with applicable ethical, institutional, and data protection requirements. A data-sharing agreement may be required before data transfer.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Jan 2026, 3 months.

Of 226 non-industry interventional studies with no phase under Musculoskeletal Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 3 months is below that.

Counting every sponsor, half of 239 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Nov 2025 → Jan 2026 and completion Dec 2025 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2025
First posted
Nov 20, 2025
StartActual
Sep 20, 2025
Primary completionActual
Jan 14, 2026was Nov 2025
CompletionActual
Nov 4, 2026was Dec 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 16, 2026
Primary completion
Nov 30, 2025→Jan 14, 2026 (actual)
Nov 16, 2026
Study completion
Dec 15, 2025→Nov 4, 2026 (actual)
Nov 16, 2026
Eligibility
6 inclusion criteria edited, 1 removed; 6 exclusion criteria edited, 2 removed
What changed in the criteria
Inclusion criteria
  • EditedAdults aged 18 to -40 years.
  • EditedRecreational or competitive athletesIndividuals with clinically diagnosed patellar tendinopathy for at least lasting ≥3 months.
  • EditedUltrasound-confirmed findings consistent with patellar tendinopathy, including tendon thickening, hypoechoic areas, tendon thickening, or neovascularization consistent with clinical diagnosis.
  • EditedPresence of painPain during tendon-loading activities (e.g., jumping, running, or squatting).
  • RemovedAbility to perform maximal voluntary isometric contractions of the quadriceps.
  • EditedAbility to perform maximal voluntary isometric quadriceps contractions and comply with all studyexperimental procedures and attend all experimental sessions.
  • EditedWrittenAbility and willingness to provide written informed consent obtained prior to participation.
Exclusion criteria
  • EditedPrevious kneeKnee surgery or traumatic knee injury within the pastpreceding 12 months.
  • EditedCompletePartial or partialcomplete patellar tendon rupture.
  • RemovedNeurological disorders affecting lower limb strength or motor control.
  • RemovedContraindications to electrical stimulation, including implanted electrical devices (e.g., pacemaker).
  • EditedCurrentNeurological or neuromuscular disorders affecting lower-limb motor function, including radiculopathy or peripheral neuropathy.
  • EditedSkinContraindications to electrical stimulation or percutaneous procedures, including implanted electrical devices, skin infections, or open wounds, or dermatological conditions at the stimulation site.
  • EditedUse of analgesics, or anti-inflammatoriesinflammatory medications, or receipt of corticosteroid injections, within the pastpreceding 48 hours.
  • EditedParticipation in another interventional study inwithin the previouspreceding 30 days.
Nov 16, 2026
Interventions
Added Device: High-frequency percutaneous femoral nerve stimulation·Device: Low-frequency percutaneous femoral nerve stimulation·Device: Transcutaneous electrical nerve stimulation; removed Device: Electrical stimulation. Arm changed Transcutaneous Electrical Nerve Stimulation (TENS)→Sensory-level transcutaneous femoral nerve stimulation (s-TENS). Arms added: High-frequency percutaneous peripheral nerve stimulation (HF-pPNS)·Low-frequency percutaneous peripheral nerve stimulation (LF-pPNS); arms removed: High-Frequency PPNS (100 Hz)·Low-Frequency PPNS (2 Hz)
Nov 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in Quadriceps Maximal Isometric Voluntary Contraction (MVC)Time frame: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.
Nov 16, 2026
Secondary outcomes
2 edited, 1 description edited
What changed in the outcomes
  • EditedChange in Quadriceps Rate of Force Development (RFD 0-250 ms)Time frame: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.
  • ChangedBefore Change in Quadriceps Impulse (0-250 ms)Now Pain Intensity Evoked by Quadriceps ContractionTime frame: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention. → Immediately after post-intervention quadriceps strength testing during each experimental session.
  • DescriptionIncidence of Adverse Events Assessed Through Post-Intervention Questionnaires: how it is measured was reworded
Nov 16, 2026
Title
Frequency-Dependent Effects of Percutaneous Femoral Nerve Stimulation on Quadriceps Strength in Athletes With Patellar Tendinopathy
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Completed
    Primary completion Nov 30, 2025→Jan 14, 2026 (now actual)
    Study completion Dec 15, 2025→Nov 4, 2026 (now actual)
    Eligibility 6 inclusion criteria edited, 1 removed; 6 exclusion criteria edited, 2 removed
    What changed in the criteria
    Inclusion criteria
    • EditedAdults aged 18 to -40 years.
    • EditedRecreational or competitive athletesIndividuals with clinically diagnosed patellar tendinopathy for at least lasting ≥3 months.
    • EditedUltrasound-confirmed findings consistent with patellar tendinopathy, including tendon thickening, hypoechoic areas, tendon thickening, or neovascularization consistent with clinical diagnosis.
    • EditedPresence of painPain during tendon-loading activities (e.g., jumping, running, or squatting).
    • RemovedAbility to perform maximal voluntary isometric contractions of the quadriceps.
    • EditedAbility to perform maximal voluntary isometric quadriceps contractions and comply with all studyexperimental procedures and attend all experimental sessions.
    • EditedWrittenAbility and willingness to provide written informed consent obtained prior to participation.
    Exclusion criteria
    • EditedPrevious kneeKnee surgery or traumatic knee injury within the pastpreceding 12 months.
    • EditedCompletePartial or partialcomplete patellar tendon rupture.
    • RemovedNeurological disorders affecting lower limb strength or motor control.
    • RemovedContraindications to electrical stimulation, including implanted electrical devices (e.g., pacemaker).
    • EditedCurrentNeurological or neuromuscular disorders affecting lower-limb motor function, including radiculopathy or peripheral neuropathy.
    • EditedSkinContraindications to electrical stimulation or percutaneous procedures, including implanted electrical devices, skin infections, or open wounds, or dermatological conditions at the stimulation site.
    • EditedUse of analgesics, or anti-inflammatoriesinflammatory medications, or receipt of corticosteroid injections, within the pastpreceding 48 hours.
    • EditedParticipation in another interventional study inwithin the previouspreceding 30 days.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in Quadriceps Maximal Isometric Voluntary Contraction (MVC)Time frame: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.
    Secondary outcomes 2 edited, 1 description edited
    What changed in the outcomes
    • EditedChange in Quadriceps Rate of Force Development (RFD 0-250 ms)Time frame: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.
    • ChangedBefore Change in Quadriceps Impulse (0-250 ms)Now Pain Intensity Evoked by Quadriceps ContractionTime frame: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention. → Immediately after post-intervention quadriceps strength testing during each experimental session.
    • DescriptionIncidence of Adverse Events Assessed Through Post-Intervention Questionnaires: how it is measured was reworded
    Interventions Added Device: High-frequency percutaneous femoral nerve stimulation·Device: Low-frequency percutaneous femoral nerve stimulation·Device: Transcutaneous electrical nerve stimulation; removed Device: Electrical stimulation. Arm changed Transcutaneous Electrical Nerve Stimulation (TENS)→Sensory-level transcutaneous femoral nerve stimulation (s-TENS). Arms added: High-frequency percutaneous peripheral nerve stimulation (HF-pPNS)·Low-frequency percutaneous peripheral nerve stimulation (LF-pPNS); arms removed: High-Frequency PPNS (100 Hz)·Low-Frequency PPNS (2 Hz)
    Title Frequency-Dependent Effects of Percutaneous Femoral Nerve Stimulation on Quadriceps Strength in Athletes With Patellar Tendinopathy
    + 7 other changes: index terms, verification date, description, conditions, contact details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07237867
Responsible party
Xavier Picañol Parraga (Phd in Neuroscience, Hospital Clinic of Barcelona) — Principal investigator
First posted
Nov 20, 2025
Start date
Sep 20, 2025
Primary completion
Jan 14, 2026
Completion
Nov 4, 2026
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion